Novartis AG Acquires Chinook Therapeutics

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Novartis Acquires Anthos Therapeutics for Up to $3.1 Billion

February 11, 2025

Biotechnology

Novartis has completed the acquisition of Anthos Therapeutics, a Blackstone Life Sciences–backed clinical-stage biopharmaceutical company, in a deal valued at up to $3.1 billion, including $925 million paid upfront. The acquisition gives Novartis ownership of abelacimab, a Phase 3 factor XI inhibitor being developed to prevent stroke and cancer-associated thrombosis, with remaining milestone payments contingent on regulatory and commercial outcomes.

Amgen Acquires ChemoCentryx

August 4, 2022

Biotechnology

Amgen agreed to acquire ChemoCentryx for $52 per share in cash (approximately $3.7 billion enterprise value), gaining TAVNEOS (avacopan), a first-in-class oral therapy for ANCA-associated vasculitis. The deal, unanimously approved by both boards, is intended to strengthen Amgen's inflammation and nephrology portfolio and is expected to close following stockholder and regulatory approvals.

BioNTech Acquires Neon Therapeutics

January 16, 2020

Biotechnology

BioNTech SE will acquire Neon Therapeutics, Inc. in an all-stock transaction valued at approximately $67.0 million. Neon, a Cambridge-based developer of neoantigen-targeted T cell therapies, will become a wholly owned subsidiary of BioNTech to expand BioNTech’s T cell therapy capabilities and U.S. presence.

Novartis Acquires Gyroscope Therapeutics

December 22, 2021

Biotechnology

Novartis has agreed to acquire UK-based Gyroscope Therapeutics for $800 million upfront with up to $700 million in contingent milestone payments, adding GT005 — an AAV2-based, one-time investigational gene therapy for geographic atrophy secondary to AMD — and early-stage retinal assets to its ophthalmology pipeline. The transaction is subject to customary closing conditions and regulatory approvals; Gyroscope will continue to operate independently until closing.

Pfizer Acquires Seagen for $43 Billion

December 14, 2023

Biotechnology

Pfizer completed the acquisition of Seagen, acquiring all outstanding Seagen common stock for $229 per share in cash in a transaction valued at approximately $43 billion. The deal adds Seagen's ADC technology, four in-line oncology medicines and a large early-stage pipeline to Pfizer's oncology portfolio, expanding Pfizer's capabilities and doubling its oncology pipeline.